Literature DB >> 11907163

Inhibitors of ATP-binding cassette transporters suppress interleukin-12 p40 production and major histocompatibility complex II up-regulation in macrophages.

György Haskó1, Edwin A Deitch, Zoltán H Németh, David G Kuhel, Csaba Szabó.   

Abstract

ATP-binding cassette (ABC) transporters are a large family of proteins whose role is to translocate various substances across biological membranes. They include the Tangier disease protein ABC1, sulfonylurea receptors (SUR), multidrug resistance protein (MDR), and cystic fibrosis transmembrane regulator (CFTR). In the current study, we investigated the involvement of ABC transporters in the regulation of lipopolysaccharide (LPS) and/or interferon (IFN)-gamma-induced interleukin (IL)-12 p40 and tumor necrosis factor (TNF)-alpha production, nitric oxide formation, as well as major histocompatibility complex II up-regulation in macrophages. The general ABC transporter inhibitor glibenclamide suppressed both IL-12 p40 and nitric oxide production. However, glibenclamide failed to affect the production of TNF-alpha. The selective ABC1 inhibitors 4,4'-diisothiocyanostilbene-2,2'-disulfonic acid and sulfobromophthalein mimicked the suppressive effect of glibenclamide on IL-12 p40 production. On the other hand, both the MDR inhibitor verapamil and CFTR blocker 2,2'-iminodibenzoic acid failed to suppress the production of IL-12 p40. Furthermore, selective inhibitors and activators of SURs were without effect. In agreement with the pharmacological data, macrophages expressed mRNA for ABC1, but not SURs or CFTR. Intracellular levels of IL-12 p40 were decreased by glibenclamide, suggesting that glibenclamide does not affect IL-12 p40 secretion. The effect of glibenclamide did not involve an interference with the activation of the p38 and p42/44 mitogen-activated protein kinases or c-Jun kinase. Glibenclamide also suppressed IFN-gamma-induced up-regulation of major histocompatibility complex II. Taken together, our results indicate that ABC proteins regulate LPS and/or IFN-gamma-induced macrophage activation.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11907163     DOI: 10.1124/jpet.301.1.103

Source DB:  PubMed          Journal:  J Pharmacol Exp Ther        ISSN: 0022-3565            Impact factor:   4.030


  6 in total

1.  Regulation of chemokine expression by NaCl occurs independently of cystic fibrosis transmembrane conductance regulator in macrophages.

Authors:  Amanda G Kostyk; Karen M Dahl; Murry W Wynes; Laurie A Whittaker; Daniel J Weiss; Roberto Loi; David W H Riches
Journal:  Am J Pathol       Date:  2006-07       Impact factor: 4.307

2.  Human guanylate binding protein-1 is a secreted GTPase present in increased concentrations in the cerebrospinal fluid of patients with bacterial meningitis.

Authors:  Elisabeth Naschberger; Clara Lubeseder-Martellato; Nadine Meyer; Ruth Gessner; Elisabeth Kremmer; Andrè Gessner; Michael Stürzl
Journal:  Am J Pathol       Date:  2006-09       Impact factor: 4.307

3.  Retinol binding protein status in relation to ocular surface changes in patients with cystic fibrosis treated with daily vitamin A supplements.

Authors:  Malgorzata Mrugacz; Jolanta Tobolczyk; Alina Minarowska
Journal:  Eur J Pediatr       Date:  2004-11-20       Impact factor: 3.183

4.  Glyburide is anti-inflammatory and associated with reduced mortality in melioidosis.

Authors:  Gavin C K W Koh; Rapeephan R Maude; M Fernanda Schreiber; Direk Limmathurotsakul; W Joost Wiersinga; Vanaporn Wuthiekanun; Sue J Lee; Weera Mahavanakul; Wipada Chaowagul; Wirongrong Chierakul; Nicholas J White; Tom van der Poll; Nicholas P J Day; Gordon Dougan; Sharon J Peacock
Journal:  Clin Infect Dis       Date:  2011-02-03       Impact factor: 9.079

5.  Calcitriol and TO-901317 interact in human prostate cancer LNCaP cells.

Authors:  Jing-Huan Wang; Pentti Tuohimaa
Journal:  Gene Regul Syst Bio       Date:  2008-03-17

6.  Non-apoptotic toxicity of Pseudomonas aeruginosa toward murine cells.

Authors:  Sanhita Roy; Tracey Bonfield; Alan M Tartakoff
Journal:  PLoS One       Date:  2013-01-24       Impact factor: 3.240

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.